Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
P/E ratio for Beyond Air, Inc. (XAIR)
P/E ratio as of 2024: -0.87
According to Beyond Air, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.87. At the end of 2023 the company had a P/E ratio of -3.62.
P/E ratio history for Beyond Air, Inc. from 2014 to 2024
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2024 | -0.87 |
| 2023 | -3.62 |
| 2022 | -3.97 |
| 2021 | -4.33 |
| 2020 | -4.62 |
| 2019 | -6.09 |
| 2018 | -1.00 |
| 2017 | -2.24 |
| 2016 | -19.95 |
| 2015 | -1.73 |
| 2014 | -5.06 |